Sign In
|
Register
|
About San Anselmo
|
Contact Us
San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast
|
Traffic
San Anselmo News
Local News
Bay Area News
Business
Technology
Real Estate
Sports
High School Sports
San Anselmo Gas Prices
Ski And Snow Reports
Financial Markets
Bakery
Brew Pubs
Coffee Houses
Eating Places
Fast Food
Seafood
Sports Bars
Steaks, Chops
Wine
Bars and Lounges
Dinner & Music Theatres
Events & Concerts
Live Music
Night Clubs
Attractions
Antiques
Nightlife
Family Activities
Arts & Culture
Annual Events
Accommodations
Hotel and Motel Management
Hotels & Resorts
Apartments
Apartment Finding & Rentals
Apartments
Senior Apartments
Art & Culture
Galleries & Dealers
Museums
Theatres
Associations, Foundations and Organizations
Business & Professional Clubs
Chambers of Commerce
Civic, Social and Fraternal
Non-Profits
Professional & Trade Associations
Sales Organizations
Attractions & Entertainment
Amusement & Water Parks
Galleries
General Attractions
Museums
Parks & Preserves
Theatre
Automotive
Dealers - Antique & Classic
Dealers - New
Dealers - Used
Motorcycles
Parts & Supplies
Repair & Service
Beauty & Fitness
Barbers
Beauty Salons
Dance Clubs & Studios
Fitness Programs
Health Clubs & Gyms
Massage
Business & Professional Services
Appraisers
Building Maintenance & Janitorial
Business Legal Services
Communications Services
Computer & Audio Visual Services
Consultants
Copier & Fax Services, Equipment
Data Processing Service
Durable Goods
Employment Services, Placement & Agencies
Engineer and Architect Services
Equipment & Supplies, Commercial & Industrial
Graphic Design & Art
Human Resource Services
Management Services
Marketing & Advertising Services
Media Services
Office Furniture, Equipment & Supplies
Photography
Printing & Publishing
Public Relations & Publicity
Research
Security & Investigative Services
Shipping, Packaging & Postal Services
Signs & Banners
Staffing & Support Services
Telecommunications
Trucking & Hauling
Video Production
Commercial Contractors
Concierge & Lifestyle Services
Contractors
Architects
Building Contractors & Consultants
Electric
General Contractors
Heating, Cooling & AC
Landscaping
Painting & Wallcovering
Plumbing
Special Trade Contractors
Domestic Services
Child Care Services
Pet Sitting and Day Care
Education
Art Education
Colleges & Universities
Cont. Education
Elementary Schools
High Schools
Libraries
Middle Schools
Preschools & Childcare
Private & Parochial
Public
Tutoring
Employment
Employment Agencies
Find or Post a Job
Temporary Help & Employment Contractors
Financial Services
Accountants & Tax
Appraisers
Banks & Credit Unions
Bookkeeping
Financial Brokers and Dealers
Financial Consultants
Financial Planning and Services
Investments
Loans
Misc. Financial Services
Mortgage Lenders
Personal
Government
Post Offices
Health and Medicine
Alternative Medicine / Acupuncture
Animal Health
Chiropractors
Counseling
Dentistry
Drug Stores & Pharmacies
Eye Care
Health Care Professionals
Home Health Care
Hospitals & Clinics
Massage
Medical Doctors
Mental Health
Physical Therapist
Physicians & Surgeons
Social Services
Specialists - Health Care Professionals
Home & Garden
Accessories
Bed & Bath
Cabinets, Racks & Shelves
Carpets & Rugs
Cleaning Supplies & Services
Contractors
Electric
Floor Coverings
Furniture
Heating, Cooling & AC
Home Improvement Centers
Kitchen
Lamps & Lighting
Lawn & Garden
Masonry & Stone Work
Nurseries & Garden Centers
Painting & Wallcoverings
Plumbing
Tree Services
Insurance
Agents & Brokers
Auto
Health
Home
Life
Pets
Legal
Attorneys
Legal Services
Manufacturing & Industrial
Agriculture
Food & Beverage
Media
Cable & Pay TV Services
Print Publications
Television Stations
Meeting & Event Planning
Audio & Visual
Event Facilities
Exhibit Designers
Lodging
Meeting Planners
Party Rentals & Entertainment
Travel Arrangement & Services
Miscellaneous
Nightlife
Bars and Lounges
Dinner & Music Theatres
Events & Concerts
Live Music
Night Clubs
Personal Service
Barbers, Beauty Salons & Spas
Shoe Repair
Pets
Pet Shops
Training
Veterinary Hospitals
Real Estate
Appraisers
Commercial
Condominiums
Developers
Mortgage Lenders
Property Management
Real Estate Agents and Brokers
Residential
Religion
Relocation
Movers
Storage
Restaurants
Bakery
Brew Pubs
Coffee Houses
Eating Places
Fast Food
Seafood
Sports Bars
Steaks, Chops
Wine
Shopping
Accessories
Antiques
Books
Bridal Shops
Cellular & Wireless
Children's and Infants Clothing
Clothing
Computer and Computer Software
Convenience Stores
Department Stores
Discount Stores
Flowers
Furniture
Gas Stations
Gifts & Specialty Shops
Gourmet & Specialty Foods
Grocery Stores
Health Food Stores
Home Improvement
Indian Arts & Crafts - Retail
Jewelry
Men's Clothing Stores
Notions
Office Supplies & Service
Pharmacies
Repair Shops
Resale Shops
Shoe Stores
Sporting Goods
Thrift Stores
Videos
Women's Clothing Stores
Spas
Beauty Salons
Sports & Recreation
Bicycles
Dance Clubs & Studios, Instruction
Health Clubs
Instruction
Recreation Facilities
Sporting Goods
Technology
Communications
Computer Maintenance and Repair
Computer Services & Consultants
E-commerce
Internet Advertising & Services
Semiconductor
Software
Web Design
Web Development
Travel & Transportation
Hotels & Resorts
Taxi, Limousine & Shuttle
Travel Agencies
Weddings
Bridal Shops
Entertainment
Florists
Health & Beauty
Photographers & Videographers
Apartments
Classifieds
Cars
Forums
Coupons
News Archives
Contests
Jobs
Search Hotels in San Anselmo
CHECK-IN:
CHECK-OUT:
ROOMS:
1
2
3
4
Find A Business
or
Browse Listings
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
54.96
+0.19 (+0.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi-Aventis S.A. ADR
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
October 11, 2024
Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on...
Via
Benzinga
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
October 10, 2024
Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued.
Via
Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
October 07, 2024
Via
Benzinga
2 Artificial Intelligence Stocks That Could Deliver Explosive Gains
October 07, 2024
These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
October 04, 2024
The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5...
Via
Benzinga
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.
October 03, 2024
SANOFI-ADR (NASDAQ:SNY) is an undervalued gem with solid fundamentals.
Via
Chartmill
Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati
October 04, 2024
Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes milestone payments and is expected to close by the end of 2024.
Via
Benzinga
Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses
October 04, 2024
Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization...
Via
Benzinga
Exposures
Product Safety
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Week In Review: Zenas Raises $259 Million In IPO
September 28, 2024
It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259...
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
September 27, 2024
The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3...
Via
Benzinga
Exposures
Product Safety
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
September 27, 2024
The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.
Via
Investor's Business Daily
Exposures
Product Safety
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
September 27, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
September 27, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
September 25, 2024
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to...
Via
Benzinga
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
September 25, 2024
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...
Via
Benzinga
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
September 25, 2024
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks...
Via
Benzinga
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
September 24, 2024
Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?
Via
MarketBeat
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
September 23, 2024
Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for Parkinson's disease.
Via
Benzinga
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
September 23, 2024
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. Sarclisa is the...
Via
Benzinga
Exposures
Product Safety
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
September 20, 2024
FTC files a complaint against CVS, Cigna, and UnitedHealth's PBMs, accusing them of inflating insulin prices through a rebate-driven system. The case aims to address unfair practices and improve access...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
September 20, 2024
Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed...
Via
Benzinga
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
September 20, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
September 18, 2024
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from...
Via
Benzinga
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
September 13, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
Should You Buy Novavax Stock After This Regulatory Win?
September 13, 2024
The biotech continues to earn important wins, but is it enough?
Via
The Motley Fool
Biotech Breakout: Stocks for Your Watchlist
September 12, 2024
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150.
Via
MarketBeat
Topics
ETFs
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
September 11, 2024
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.
Via
Benzinga
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
September 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
About Us
|
Contact Us
|
Privacy Policy
|
User Agreement
|
Advertise With Us
|
Site Map
San Anselmo
|
San Anselmo News
|
San Anselmo Travel
|
Restaurants
|
Nightlife
|
Things To Do
|
Shopping
|
Calendar
|
Directory
|
Real Estate
|
Blog
|
More
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.